Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Effects of mRNA secondary structure on the expression of HEV ORF2 proteins in Escherichia coli
N Behloul, W Wei, S Baha, Z Liu, J Wen, J Meng - Microbial Cell Factories, 2017 - Springer
Background Viral protein expression in Escherichia coli (E. coli) is a powerful tool for
structural/functional studies as well as for vaccine and diagnostics development. However …
structural/functional studies as well as for vaccine and diagnostics development. However …
Modulation of heterologous expression from PBAD promoter in Escherichia coli production strains
Promoter P BAD is frequently used for heterologous gene expression due to several
advantages, such as moderately high expression levels, induction by an inexpensive and …
advantages, such as moderately high expression levels, induction by an inexpensive and …
Immune response induced by recombinant pres2/S-protein and a pres2-S-protein fused with a core 18-27 antigen fragment of hepatitis B virus compared to …
EG Parizad, AA Imani Fooladi, H Sedighian, E Behzadi… - Virus Genes, 2023 - Springer
Although comprehensive vaccination is the cornerstone of public health programs to control
hepatitis B virus (HBV) infections, 5% of people who receive the existing vaccine do not …
hepatitis B virus (HBV) infections, 5% of people who receive the existing vaccine do not …
Comparison of Immune Response in Mice Immunized with Recombinant PreS2/S-C18-27 Protein Derived from Hepatitis B Virus with Commercial Vaccine
EG Parizad, AAI Fooladi, H Sedighian… - Iranian Journal of …, 2022 - pmc.ncbi.nlm.nih.gov
Background & Objective: The vaccine available to prevent Hepatitis B virus disease is
ineffective in 5% of people due to the use of HBsAg as a weak immunogenic factor. In the …
ineffective in 5% of people due to the use of HBsAg as a weak immunogenic factor. In the …
[PDF][PDF] Immune Response in Mice Immunized with Recombinant PreS2/S-C18-27 Protein from Hepatitis B Virus Compared with Commercial Vaccine
E Gholami Parizad, AA Imani Fooladi… - Iranian journal of …, 2022 - ijp.iranpath.org
Background & Objective: The vaccine available to prevent Hepatitis B virus disease is
ineffective in 5% of people due to the use of HBsAg as a weak immunogen. In the present …
ineffective in 5% of people due to the use of HBsAg as a weak immunogen. In the present …
[PDF][PDF] Production of hepatitis B surface antigen (HBsAg) from Escherichia coli for development of diagnostic kit
K Bhavya, N Guleria, RG PH, S Kumar - Pharma Inno, 2016 - academia.edu
Hepatitis B virus (HBV) infection is a worldwide health problem, which can lead to severe
liver disease mainly hepatocellular carcinoma and cirrhosis. The present investigation lays …
liver disease mainly hepatocellular carcinoma and cirrhosis. The present investigation lays …